Nozoe Tadahiro, Matono Rumi, Ijichi Hideki, Ohga Takefumi, Ezaki Takahiro
Department of Surgery, Fukuoka Higashi Medical Center, Koga, Japan.
Int Surg. 2014 Sep-Oct;99(5):512-7. doi: 10.9738/INTSURG-D-13-00118.1.
The Glasgow Prognostic Score (GPS), an inflammation-based score, has been used to predict the biologic behavior of malignant tumors. The aim of the current study was to elucidate a further significance of GPS in colorectal carcinoma. Correlation of GPS and modified GPS (mGPS), which are composed of combined score provided for serum elevation of C-reactive protein and hypoalbuminemia examined before surgical treatment, with clinicopathologic features was investigated in 272 patients with colorectal carcinoma. Survival of GPS 1 patients was significantly worse than that of GPS 0 patients (P= 0.009), and survival of GPS 2 patients was significantly worse than that of GPS 1 patients (P < 0.0001). Similarly, survival of mGPS 1 patients was significantly worse than that of mGPS 0 patients (P = 0.009), and survival of mGPS 2 patients was significantly worse than that of mGPS 1 patients (P = 0.0006). Multivariate analysis demonstrated that GPS (P < 0.0001) as well as tumor stage (P= 0.004) and venous invasion (P = 0.011) were factors independently associated with worse prognosis. Both GPS and mGPS could classify outcome of patients with a clear stratification, and could be applied as prognostic indicators in colorectal carcinoma.
格拉斯哥预后评分（GPS）是一种基于炎症的评分系统，已被用于预测恶性肿瘤的生物学行为。本研究的目的是阐明GPS在结直肠癌中的进一步意义。我们在272例结直肠癌患者中研究了GPS和改良GPS（mGPS）与临床病理特征的相关性，GPS和mGPS由手术治疗前检测的血清C反应蛋白升高和低白蛋白血症的综合评分组成。GPS 1分患者的生存率显著低于GPS 0分患者（P = 0.009），GPS 2分患者的生存率显著低于GPS 1分患者（P < 0.0001）。同样，mGPS 1分患者的生存率显著低于mGPS 0分患者（P = 0.009），mGPS 2分患者的生存率显著低于mGPS 1分患者（P = 0.0006）。多因素分析表明，GPS（P < 0.0001）以及肿瘤分期（P = 0.004）和静脉侵犯（P = 0.011）是与预后较差独立相关的因素。GPS和mGPS都能对患者的预后进行明确分层，可作为结直肠癌的预后指标。
